{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T06:12:47Z","timestamp":1791094367799,"version":"4.1.0"},"reference-count":53,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,6,15]],"date-time":"2013-06-15T00:00:00Z","timestamp":1371254400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2013,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Tremendous progress has been made in the care of individuals with sickle cell over the past several decades. Major successes have been comprehensive infection prophylaxis, prediction and prevention of stroke, and better transfusion care, the latter including both prevention of alloimmunization and treatment of iron overload. However, definitive therapies remain limited to hydroxycarbamide (hydroxyurea) and stem cell transplantation, both of which have been in use for at least two decades. Despite knowing the progressive natural history of the disease with organ dysfunction, failure, and ultimately death at a young age, definitive therapies are considered for only a small proportion of individuals. Consequently, while life expectancy has improved dramatically from the last century, the ongoing pace of advancement has slowed or stalled. We believe that it is time to broaden the use of definitive therapy for those with asymptomatic disease, being cautiously more aggressive in our approach.<\/jats:p>","DOI":"10.1111\/bjh.12413","type":"journal-article","created":{"date-parts":[[2013,6,15]],"date-time":"2013-06-15T07:36:22Z","timestamp":1371281782000},"page":"455-464","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Sickle cell disease: time for a closer look at treatment options?"],"prefix":"10.1111","volume":"162","author":[{"given":"Sujit","family":"Sheth","sequence":"first","affiliation":[{"name":"Weill Cornell Medical College New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Licursi","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center New York NY USA"},{"name":"New York Presbyterian Hospital New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,6,15]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-326298"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2007.00725.x"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807023390102"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0027-9684(15)30725-2"},{"key":"e_1_2_13_6_1","first-page":"59","article-title":"Results and current indications of bone marrow allograft in sickle cell disease","volume":"47","author":"Bernaudin F.","year":"1999","journal-title":"Pathologie\u2010Biologie"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-079665"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2011.06.002"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-438408"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-12-200806170-00220"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199505183322001"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21905"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2011-3049"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-272682"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.6.1960.bloodjournal8861960"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035477"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2009.12.022"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1910.00050330050003"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22879"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904971"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-332510"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(03)00192-7"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198409203111207"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.01.019"},{"key":"e_1_2_13_25_1","first-page":"1550","article-title":"Safety of hydroxyurea in children with sickle cell anemia: results of the HUG\u2010KIDS study, a phase I\/II trial. Pediatric Hydroxyurea Group","volume":"94","author":"Kinney T.R.","year":"1999","journal-title":"Blood"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.08.016"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-2090"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08395.x"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.358"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.06.036673"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24176"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06592.x"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199406093302303"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-233700"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.02.002"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1081\/HEM-100103065"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.05.013"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2011.1.273"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704795"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/08830738050200020301"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.13.1645"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21699"},{"key":"e_1_2_13_43_1","unstructured":"Steiner C.A.&Miller J.L.(2006)Sickle Cell Disease Patients in U.S. Hospitals 2004: Statistical Brief #21. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Health Care Policy and Research (US); 2006."},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2011.1.434"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-419879"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701291"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.562"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-221333"},{"key":"e_1_2_13_49_1","first-page":"1918","article-title":"Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease","volume":"95","author":"Walters M.C.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2001.v7.pm11787529"},{"key":"e_1_2_13_51_1","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2001.116935"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60355-3"},{"key":"e_1_2_13_53_1","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1182\/blood.V96.7.2369","article-title":"Financial analysis of chronic transfusion for stroke prevention in sickle cell disease","volume":"96","author":"Wayne A.S.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_13_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2008.09.052"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12413","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12413","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T21:01:17Z","timestamp":1696280477000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,15]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["10.1111\/bjh.12413"],"URL":"https:\/\/doi.org\/10.1111\/bjh.12413","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,15]]},"assertion":[{"value":"2013-06-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}